Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

Merrimack Pharmaceuticals' stock was trading at $3.91 at the beginning of the year. Since then, MACK stock has increased by 204.1% and is now trading at $11.89.
View the best growth stocks for 2022 here.

Merrimack Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 844,700 shares, an increase of 226.0% from the October 31st total of 259,100 shares. Based on an average daily trading volume, of 625,900 shares, the days-to-cover ratio is currently 1.3 days. Currently, 7.5% of the company's stock are sold short.
View Merrimack Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our MACK earnings forecast.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.14.

Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Merrimack Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (8.21%), Dimensional Fund Advisors LP (3.52%), Nantahala Capital Management LLC (3.20%), Sepio Capital LP (2.20%), BlackRock Inc. (1.54%) and Two Sigma Investments LP (0.16%). Insiders that own company stock include Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends.

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MACK stock can currently be purchased for approximately $11.89.

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $159.44 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

The company employs 426 workers across the globe.

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-441-1000, via email at ir@merrimack.com, or via fax at 617-491-1386.